Jean Dinh

Jean Dinh

Auto-generated profile, based on publicly available information

Jean Dinh

Certara Predictive Technologies, Certara UK Limited, Sheffield, UK

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2024 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
TJTrevor Nigel Johnson
Trevor Nigel Johnson
HBHannah Batchelor
Hannah Batchelor
JGJan Goelen
Jan Goelen
RHRichard Horniblow
Richard Horniblow
JDJean Dinh
Jean Dinh
Pediatric physiologically‐based modeling in drug development has grown in the past decade and optimizing the underlying systems parameters is important in relation to overall performance. In this study, variation of clinical oral bioavailability of midazolam as a function of age is used to assess the underlying ontogeny models for intestinal CYP3A4. Data on midazolam bioavailability in adults and children and different ontogeny patterns for intestinal CYP3A4 were first collected from the literature. A pediatric PBPK model was then used to assess six different ontogeny models in predicting bioavailability from preterm neonates to adults. The average fold error ranged from 0.7 to 1.38, with the rank order of least to most biased model being No Ontogeny < Upreti = Johnson < Goelen < Chen < Kiss. The absolute average fold error ranged from 1.17 to 1.64 with the rank order of most to least precise being Johnson > Upreti > No Ontogeny > Goelen > Kiss > Chen. The optimal ontogeny model is difficult to discern when considering the possible influence of CYP3A5 and other population variability; however, this study suggests that from term neonates and older a faster onset Johnson model with a lower fraction at birth may be close to this. For inclusion in other PBPK models, independent verification will be needed to confirm these results. Further research is needed in this area both in terms of age‐related changes in midazolam and similar drug bioavailability and intestinal CYP3A4 ontogeny.

17 July 2025 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
UEUdoamaka Ezuruike
Udoamaka Ezuruike
JDJean Dinh
Jean Dinh
EEEman El-Khateeb
Eman El-Khateeb
ABAlex Blenkinsop
Alex Blenkinsop
OHOliver James Hatley
Oliver James Hatley
IGIain Gardner
Iain Gardner
Ethnic variabilities can affect the outcome of drug pharmacokinetics (PK) and drug–drug interactions (DDI). This work aimed to develop four North American (NA) sub‐populations: White, African American, Asian American, and Hispanic_Latino suitable for physiologically based pharmacokinetic (PBPK) modeling and simulations. Demographic data and tissue weight/volume, blood flows, cardiac output, plasma protein levels, hematocrit, enzyme and transporter abundances/frequencies, serum creatinine, glomerular filtration rate, and gastrointestinal transit times for the different populations were collated. Equations describing various covariate relationships for these physiological parameters were developed for each ethnicity. Some key population differences that can affect drug PK were higher CYP3A5 and OATP1B1 population mean abundances for African Americans and lower CYP3A4 and OATP1B1 population mean abundances for Asian Americans. The most common CYP2C9 alleles in the White as well as the Asian populations are the *1, *2, and *3 alleles. However, additional lower‐activity alleles (*5, *6, *8, and *11) were also shown to occur among the African Americans and Hispanic_Latino subjects. Clinical studies reporting population specific PK profiles (6 studies) or results from a mixed NA population (14 studies including 6 DDI studies) were simulated, and the simulated data were within two‐fold of the observed data. PBPK simulations using the 4 NA population files and repaglinide as a probe compound predicted significant differences in the drug exposure for the Asians, African Americans, and White subjects. In conclusion, the developed population files can aid drug development for specific subgroups of the diverse NA population by accounting for variabilities in drug kinetics and DDI consequences.


4 November 2025 in The AAPS Journal
Verified
Journal Article
Closed access
PDF file
HMHarry P. Moore
Harry P. Moore
KCKuan-Fu Chen
Kuan-Fu Chen
AHAki T. Heikkinen
Aki T. Heikkinen
SNSibylle Neuhoff
Sibylle Neuhoff
UEUdoamaka Ezuruike
Udoamaka Ezuruike
FSFelix Stader
Felix Stader